左氧氟沙星与头孢呋辛治疗肺炎的药物经济学分析

2020-09-02 06:41:15陈桂香朱碧媛赵思婷
中外医学研究 2020年21期
关键词:左氧氟沙星

陈桂香 朱碧媛 赵思婷

【摘要】 目的:探究左氧氟沙星与头孢呋辛治疗肺炎的药物经济学分析。方法:按照随机数字排序将所选取的肺炎患者分组,左氧氟沙星组(LE组)和头孢呋辛组(CA组),每组150例。通过分析LE组和CA组患者治疗效果、继发效应、成本-效果差异性来探究左氧氟沙星与头孢呋辛治疗肺炎患者的药物经济学分析。结果:治疗后,两组患者治疗效果相比较,差异无统计学意义(P>0.05)。治疗后,两组患者继发效应发生情况相比较,差异无统计学意义(P>0.05)。在有效率相同的情况下,LE组患者每增加1%,所需治疗费用就增加(22.69±5.35)元,CA组需增加(26.23±4.83)元。结论:左氧氟沙星与头孢呋辛对肺炎患者均有一定的治疗效果,但前者治疗所需成本较低。

【关键词】 左氧氟沙星 头孢呋辛 药物经济学 肺炎

doi:10.14033/j.cnki.cfmr.2020.21.069 文献标识码 B 文章编号 1674-6805(2020)21-0-03

Pharmacoeconomic Analysis of Levofloxacin and Cefuroxime in the Treatment of Pneumonia/CHEN Guixiang, ZHU Biyuan, ZHAO Siting. //Chinese and Foreign Medical Research, 2020, 18(21): -171

[Abstract] Objective: To explore the pharmacoeconomic analysis of Levofloxacin and Cefuroxime in the treatment of pneumonia. Method: The selected patients with pneumonia were sorted according to random numbers, Levofloxacin group (LE group) and Cefuroxime group (CA group), 150 cases in each group. The pharmacoeconomic analysis of Levofloxacin and Cefuroxime in the treatment of patients with pneumonia was explored by analyzing the differences in treatment effects, secondary effects, and cost-effectiveness analysis of patients in the LE and CA groups. Result: After treatment, the effects of the two groups were not significantly different (P>0.05). After treatment, the incidence of secondary effects in the two groups were similar (P>0.05). With the same effective rate, for every 1% increase in the LE group, the required treatment cost increased by (22.69±5.35) yuan, CA group increased by (26.23±4.83) yuan. Conclusion: Both levofloxacin and cefuroxime have a certain therapeutic effect on patients with pneumonia, but the cost of the former is relatively low.

[Key words] Levofloxacin Cefuroxime Pharmacoeconomics Pneumonia

First-authors address: Dongguan Traditional Chinese Medicine Hospital, Dongguan 523000, China

肺炎屬于临床常见疾病,小儿、老人等群体机体防御能力较弱,外部细菌病毒进行机体,导致体温升高、呼吸困难等一系列常见临床症状[1]。研究表明,肺炎产生原因有多种,营养欠缺、季节交替等均可以导致疾病产生[2]。根据大数据显示,欧洲部分发达国家每年因肺炎病死人数较多,每年因为肺炎死亡人数接近肺部恶性肿瘤[3]。随着近年来病毒所致重症肺炎的发生以及检测方法的改进,病毒性肺炎越来越受到重视,并在治疗过程中采取有效的治疗方案和药物,减少死亡率[4]。左氧氟沙星是生活中常见的抗菌药物,主要针对肺炎衣原体、革兰菌等细菌有较强的抗菌作用,临床应用较多。头孢呋辛……

登录APP查看全文

猜你喜欢
左氧氟沙星
左氧氟沙星与头孢呋辛联合阿奇霉素治疗社区获得性肺炎疗效比较
左氧氟沙星三联疗法与阿莫西林三联疗法治疗消化性溃疡的效果分析
对比分析左氧氟沙星三联疗法与阿莫西林三联疗法治疗消化性溃疡的疗效差异
左氧氟沙星联合替硝唑治疗盆腔炎的临床研究
不同喹诺酮类药物药理分析及对社区获得性肺炎的临床对比观察
慢性支气管炎应用左氧氟沙星联合氨溴索治疗的效果研究
莫西沙星治疗慢性阻塞性肺疾病急性加重期疗效和安全性的研究
不同抗生素在呼吸内科感染治疗中的临床应用
左氧氟沙星滴眼液治疗重症细菌性角膜炎和结膜炎的临床观察
我院2014—2015年左氧氟沙星不良反应与药物因素分析
上海医药(2016年1期)2016-02-22 23:43:49